However, the phase III prospective randomized controlled study (NSABP B-47) showed that adding trastuzumab to adjuvant chemotherapy did not improve invasive disease-free survival (iDFS), 5-year distant recurrence-free interval, or overall survival (OS) in HER2-low breast cancer patients (10). This evidence concerns the gene ERBB2 and breast cancer.